Neuroblastoma Paradigm for Precision Medicine

作者：Irwin Meredith S; Park Julie R^*

来源：Pediatric Clinics of North America, 2015, 62(1): 225-+.

DOI：10.1016/j.pcl.2014.09.015

• Neuroblastoma
• Risk stratification
• MYCN
• Segmental chromosome aberrations (SCA)
• ALK (anaplastic lymphoma kinase)
• Phox2B
• Myeloablative therapy (MAT)
• Immunotherapy

Neuroblastoma (NB) is the third most common pediatric cancer. Although NB accounts for 7% of pediatric malignancies, it is responsible for more than 10% of childhood cancer-related mortality. Prognosis and treatment are determined by clinical and biological risk factors. Estimated 5-year survival rates for patients with non-high-risk and high-risk NB are more than 90% and less than 50%, respectively. Recent clinical trials have continued to reduce therapy for patients with non-high-risk NB, including the most favorable subsets who are often followed with observation approaches. In contrast, high-risk patients are treated aggressively with chemotherapy, radiation, surgery, and myeloablative and immunotherapies.

• 出版日期2015-2